Healthcare & Life Sciences
Esbatech
Switzerland
acquiredacquired
acquired
Stage
About
Esbatech was a Swiss drug development company specializing in ophthalmology therapies that was acquired by Alcon (Novartis) for up to $589 million.
Explore Esbatech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.